Juliane Léger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Juliane Léger has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Paul Czernichow
Department of Pediatric Endocrinology and Diabetology and Institut National de la Santé et de la Recherche Médicale Unit 690 (J.L., D.M., C.L.M., N.T.-R., P.C.) 75019 Paris, France
5 shared publicationsCatherine Garel
Radiology Department (C.G.), Hôpital Robert Debré, 75019 Paris, France
4 shared publicationsDaniela Marinovic
Department of Pediatric Endocrinology and Diabetology and Institut National de la Santé et de la Recherche Médicale Unit 690 (J.L., D.M., C.L.M., N.T.-R., P.C.) 75019 Paris, France
2 shared publicationsAfdphe
AFDPHE: Association Française pour le Dépistage et la Prévention des Handicaps l'Enfant
1 shared publicationB Larroque
INSERM U 149, Villejuif, France
1 shared publicationC Lévy-Marchal
1 shared publication
Latest Publications
- 20 July 2007
- Published by Wiley in Clinical Endocrinology
- Vol. 67 (3) , 462-467
Predictors of late menarche and adult height in children with anorexia nervosa
Summary: Objectives The onset of anorexia nervosa (AN) during childhood can affect the timing of puberty and adult height. The aim of the study was to evaluate the determinants of late menarche and adult height in children with AN.Patients and methods We carried out a retrospective, longitudinal, university hospital‐based study. All prepubertal or early pubertal girls diagnosed with AN between 1998 and 2002 were selected for the study. Participants (n = 33) were studied at a median age of 21 (19·8–24·3) years. AN was diagnosed at 11·8 (10·7–12·3) years.Results Patients with AN reached menarche at significantly greater ages than their mothers [15·4 (13·5–16·8) vs. 13·2 (12·0–14·5) years, P < 0·01]. Chronological age at onset of AN and lowest body mass index (BMI) were important independent predictive factors for delayed menarche (P < 0·01). Adult height was 165·0 (163·0–172·0) cm, 2·5 (–1·5 to 5·0) cm above target height. Twelve patients (36%) did not reach their target height and had a median height deficit of –3·9 cm with respect to their target height. The duration of hospitalization, a marker of disease severity and chronicity, was an independent predictor of the difference between adult height and target height for a given individual (β coefficient = –0·07; P = 0·01). The other factors studied (i.e. age at onset of AN, pubertal stage at diagnosis of AN, lowest BMI reached, associated comorbidity if any, type of AN, age at menarche) had no significant effect on adult height.Conclusion The intensity of the disease affects the timing of menarche but not adult height in most patients. Hospitalization, despite often being an effective means of managing AN, does not reduce the impact of AN on growth.
- 20 July 2007
- Published by Wiley in Clinical Endocrinology
- Vol. 67 (3) , 462-467
Predictors of late menarche and adult height in children with anorexia nervosa
Summary: Objectives The onset of anorexia nervosa (AN) during childhood can affect the timing of puberty and adult height. The aim of the study was to evaluate the determinants of late menarche and adult height in children with AN.Patients and methods We carried out a retrospective, longitudinal, university hospital‐based study. All prepubertal or early pubertal girls diagnosed with AN between 1998 and 2002 were selected for the study. Participants (n = 33) were studied at a median age of 21 (19·8–24·3) years. AN was diagnosed at 11·8 (10·7–12·3) years.Results Patients with AN reached menarche at significantly greater ages than their mothers [15·4 (13·5–16·8) vs. 13·2 (12·0–14·5) years, P < 0·01]. Chronological age at onset of AN and lowest body mass index (BMI) were important independent predictive factors for delayed menarche (P < 0·01). Adult height was 165·0 (163·0–172·0) cm, 2·5 (–1·5 to 5·0) cm above target height. Twelve patients (36%) did not reach their target height and had a median height deficit of –3·9 cm with respect to their target height. The duration of hospitalization, a marker of disease severity and chronicity, was an independent predictor of the difference between adult height and target height for a given individual (β coefficient = –0·07; P = 0·01). The other factors studied (i.e. age at onset of AN, pubertal stage at diagnosis of AN, lowest BMI reached, associated comorbidity if any, type of AN, age at menarche) had no significant effect on adult height.Conclusion The intensity of the disease affects the timing of menarche but not adult height in most patients. Hospitalization, despite often being an effective means of managing AN, does not reduce the impact of AN on growth.
- 15 November 2006
- Vol. 56 (17) , 1957-62
[Normal and pathological puberty].
- Open Access
- 1 October 2006
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 91 (10) , 3947-3953
Lower Bone Mineral Content in Children with Type 1 Diabetes Mellitus Is Linked to Female Sex, Low Insulin-Like Growth Factor Type I Levels, and High Insulin Requirement
Context: Studies on bone mineral characteristics in children with type 1 diabetes mellitus (T1DM) have generated conflicting results. Objective: Our objective was to investigate bone mineral characteristics in children with T1DM and to analyze their associations with bone metabolism and the IGF-I system. Design: We recruited a cohort of Caucasian patients with T1DM for at least 3 yr and healthy children between January 2003 and June 2004. Setting: This was a university hospital-based study. Participants: A total of 127 patients and 319 controls aged 6 to 20 yr participated. Methods: Dual-energy x-ray absorptiometry was performed in patients and controls. Serum bone alkaline phosphatase, CrossLaps, IGF-I, and IGF-binding protein 3 levels were determined in patients with values analyzed using our normative data from 1150 healthy children. Results: After adjustment for age, sex, pubertal stage, and body mass index sd score, total body bone mineral content (BMC)/lean body mass was significantly lower in patients than in controls (P < 0.04). This difference was a result of the differences between the girls of the two groups. Girls with T1DM had significantly lower lumbar spine and total body BMC than control girls (P = 0.002), whereas no such difference was observed in boys. Serum bone alkaline phosphatase level was significantly lower in girls than in boys (P = 0.04). Low serum IGF-I levels and the administration of large amounts of insulin were found to have independent deleterious effects on BMC for children of all ages and both sexes, whereas disease duration and glycosylated hemoglobin levels did not. Conclusions: A sex-related difference in the impairment of bone mineral characteristics was identified in children with T1DM. Longitudinal studies are required to investigate whether boys may gain slightly less bone mass during skeletal growth.
- 1 October 2006
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 91 (10) , 3947-3953
Open AccessLower Bone Mineral Content in Children with Type 1 Diabetes Mellitus Is Linked to Female Sex, Low Insulin-Like Growth Factor Type I Levels, and High Insulin Requirement
Context: Studies on bone mineral characteristics in children with type 1 diabetes mellitus (T1DM) have generated conflicting results. Objective: Our objective was to investigate bone mineral characteristics in children with T1DM and to analyze their associations with bone metabolism and the IGF-I system. Design: We recruited a cohort of Caucasian patients with T1DM for at least 3 yr and healthy children between January 2003 and June 2004. Setting: This was a university hospital-based study. Participants: A total of 127 patients and 319 controls aged 6 to 20 yr participated. Methods: Dual-energy x-ray absorptiometry was performed in patients and controls. Serum bone alkaline phosphatase, CrossLaps, IGF-I, and IGF-binding protein 3 levels were determined in patients with values analyzed using our normative data from 1150 healthy children. Results: After adjustment for age, sex, pubertal stage, and body mass index sd score, total body bone mineral content (BMC)/lean body mass was significantly lower in patients than in controls (P < 0.04). This difference was a result of the differences between the girls of the two groups. Girls with T1DM had significantly lower lumbar spine and total body BMC than control girls (P = 0.002), whereas no such difference was observed in boys. Serum bone alkaline phosphatase level was significantly lower in girls than in boys (P = 0.04). Low serum IGF-I levels and the administration of large amounts of insulin were found to have independent deleterious effects on BMC for children of all ages and both sexes, whereas disease duration and glycosylated hemoglobin levels did not. Conclusions: A sex-related difference in the impairment of bone mineral characteristics was identified in children with T1DM. Longitudinal studies are required to investigate whether boys may gain slightly less bone mass during skeletal growth.
- 1 February 2005
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 90 (2) , 650-656
Do All Patients with Childhood-Onset Growth Hormone Deficiency (GHD) and Ectopic Neurohypophysis Have Persistent GHD in Adulthood?
Cerebral magnetic resonance imaging findings are of great value for the diagnosis of nonacquired GH deficiency (GHD), and ectopic posterior pituitary hyperintense signal (EPPHS) is a sensitive and specific indicator of hypopituitarism. It has been suggested that patients with childhood-onset GHD and EPPHS do not require additional investigation of GH secretion and should not be retested when adult height is achieved. This recommendation has never been validated through a systematic study. This study aimed to characterize the anterior pituitary function status of patients with EPPHS treated for GHD during childhood after completion of GH therapy when adult height had been achieved. Patients (n = 18; 15 males and three females) with childhood-onset GHD associated with ectopic neurohypophysis were treated with hGH (0.20 ± 0.05 mg/kg·wk) for 9.9 ± 4.0 yr (from 6.8 ± 4.7 to 17.7 ± 1.3 yr of age) with a mean height gain of 2.6 ± 1.4 sd score. GH secretion was reevaluated by arginine insulin (n = 15) or propanolol glucagon (n = 3) test after 0.5 ± 0.6 yr of GH withdrawal. At reevaluation, peak GH was more than 10 μg/liter in four patients (22%; range, 11.7–19.5 μg/liter; group I), between 5 and 10 μg/liter in three patients (17%; range, 7.3–9 μg/liter; group II), and less than 5 μg/liter in 11 patients (61%; range, 0–4.7 μg/liter; group III). A positive correlation was found between serum IGF-I and peak GH levels after attainment of adult height (P = 0.007). Only one of the seven patients who showed increased GH secretion ability in adulthood (groups I and II) demonstrated other hormonal deficiencies (gonadotropin and adrenal insufficiencies). Among the 11 patients with persistent severe GHD (group III), 10 (91%) of the 11 subjects were shown to have multiple pituitary hormone deficits after attainment of adult height. The structure of the hypothalamo-pituitary axis differs among groups [i.e. patients who showed increased GH secretion ability in adulthood (groups I and II) vs. those who remained severely GHD (group III)]. The location of the EPPHS was significantly different among groups (P < 0.003). The EPPHS was found at the median eminence in all but one of group III patients and along the pituitary stalk (proximal stalk) in all but one of group I and II patients. The pituitary stalk was visible and described as normal (n = 1) or thin (n = 6) in all group I and II patients, whereas the pituitary stalk was not visible even after enhancement in seven of the 11 group III patients (P < 0.02). The prevalence of anterior pituitary hypoplasia and the mean height gain sd score were similar in each group. In conclusion, only 61% of patients with childhood-onset GHD and EPPHS remained severely GHD, and thus suitable for GH therapy, in adulthood. Although the pathogenesis of anterior pituitary dysfunction remains unclear in patients with ectopic neurohypophysis, isolated GHD, location of EPPHS along the stalk, and visibility of the pituitary stalk on magnetic resonance imaging findings clearly represent important markers to predict a less severe form of the disease.
- 1 February 2005
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 90 (2) , 650-656
Do All Patients with Childhood-Onset Growth Hormone Deficiency (GHD) and Ectopic Neurohypophysis Have Persistent GHD in Adulthood?
Cerebral magnetic resonance imaging findings are of great value for the diagnosis of nonacquired GH deficiency (GHD), and ectopic posterior pituitary hyperintense signal (EPPHS) is a sensitive and specific indicator of hypopituitarism. It has been suggested that patients with childhood-onset GHD and EPPHS do not require additional investigation of GH secretion and should not be retested when adult height is achieved. This recommendation has never been validated through a systematic study. This study aimed to characterize the anterior pituitary function status of patients with EPPHS treated for GHD during childhood after completion of GH therapy when adult height had been achieved. Patients (n = 18; 15 males and three females) with childhood-onset GHD associated with ectopic neurohypophysis were treated with hGH (0.20 ± 0.05 mg/kg·wk) for 9.9 ± 4.0 yr (from 6.8 ± 4.7 to 17.7 ± 1.3 yr of age) with a mean height gain of 2.6 ± 1.4 sd score. GH secretion was reevaluated by arginine insulin (n = 15) or propanolol glucagon (n = 3) test after 0.5 ± 0.6 yr of GH withdrawal. At reevaluation, peak GH was more than 10 μg/liter in four patients (22%; range, 11.7–19.5 μg/liter; group I), between 5 and 10 μg/liter in three patients (17%; range, 7.3–9 μg/liter; group II), and less than 5 μg/liter in 11 patients (61%; range, 0–4.7 μg/liter; group III). A positive correlation was found between serum IGF-I and peak GH levels after attainment of adult height (P = 0.007). Only one of the seven patients who showed increased GH secretion ability in adulthood (groups I and II) demonstrated other hormonal deficiencies (gonadotropin and adrenal insufficiencies). Among the 11 patients with persistent severe GHD (group III), 10 (91%) of the 11 subjects were shown to have multiple pituitary hormone deficits after attainment of adult height. The structure of the hypothalamo-pituitary axis differs among groups [i.e. patients who showed increased GH secretion ability in adulthood (groups I and II) vs. those who remained severely GHD (group III)]. The location of the EPPHS was significantly different among groups (P < 0.003). The EPPHS was found at the median eminence in all but one of group III patients and along the pituitary stalk (proximal stalk) in all but one of group I and II patients. The pituitary stalk was visible and described as normal (n = 1) or thin (n = 6) in all group I and II patients, whereas the pituitary stalk was not visible even after enhancement in seven of the 11 group III patients (P < 0.02). The prevalence of anterior pituitary hypoplasia and the mean height gain sd score were similar in each group. In conclusion, only 61% of patients with childhood-onset GHD and EPPHS remained severely GHD, and thus suitable for GH therapy, in adulthood. Although the pathogenesis of anterior pituitary dysfunction remains unclear in patients with ectopic neurohypophysis, isolated GHD, location of EPPHS along the stalk, and visibility of the pituitary stalk on magnetic resonance imaging findings clearly represent important markers to predict a less severe form of the disease.
- 28 October 2003
- Published by Springer Nature in Pediatric Radiology
- Vol. 34 (2) , 109-113
Ultrasonographic assessment of the ectopic thyroid tissue in children with congenital hypothyroidism
Ectopic thyroid tissue as a result of thyroid developmental abnormalities is the most frequent cause of congenital hypothyroidism (CH). It is diagnosed by using radionuclide thyroid scanning.
- 28 October 2003
- Published by Springer Nature in Pediatric Radiology
- Vol. 34 (2) , 109-113
Ultrasonographic assessment of the ectopic thyroid tissue in children with congenital hypothyroidism
Ectopic thyroid tissue as a result of thyroid developmental abnormalities is the most frequent cause of congenital hypothyroidism (CH). It is diagnosed by using radionuclide thyroid scanning.
- 17 April 2003
- Published by Wiley in Clinical Endocrinology
- Vol. 58 (5) , 647-652
Presence of magnetic resonance imaging abnormalities of the hypothalamic–pituitary axis is a significant determinant of the first 3 years growth response to human growth hormone treatment in prepubertal children with nonacquired growth hormone deficiency
Summary: objective The factors influencing the highly variable growth response to GH treatment in GH‐deficient children are not fully understood. Despite a real benefit with GH treatment in term of growth response, most of these patients attain a mean adult height below their target height and the strategy to optimise final height has to be improved. The aim of this study was to investigate whether the presence of congenital abnormalities of the hypothalamic–pituitary axis on magnetic resonance imaging (MRI) could be a determinant of the growth response in nonacquired prepubertal GH‐deficient children, and to identify which pretreatment variables most significantly affect the first 3 years growth response to human GH (hGH) therapy.patients and methods The growth response to hGH treatment (0·55 ± 0·1 IU/kg/week) was evaluated in 69 prepubertal children with nonacquired GH deficiency, according to the absence (group A: chronological age = 4·8 ± 2·4 years, n= 37) or the presence (group B: chronological age = 3·4 ± 2·7 years, n= 32) of developmental abnormalities on cerebral magnetic imaging and, after controlling for GH dose, age, height, height velocity (SDS) and body mass index at start of treatment, maximum stimulated GH peak concentration, GH deficiency type (isolated vs. multiple deficiency), parental height, size at birth and sex.results After 3 years of treatment, the mean height gain was significantly higher in patients of group B vs. group A (2·2 ± 1·3 vs. 1·6 ± 1 SDS; P < 0·05). In a multiple regression analysis, age (r2 = 0·19, negatively correlated), pretreatment height velocity (r2 = 0·11, negatively correlated), GH dose (r2 = 0·05, positively correlated) and presence of magnetic resonance imaging developmental abnormalities (r2 = 0·05, positively correlated) were found to significantly explain 40% of the variability in growth response.conclusions The detection of congenital abnormalities in the hypothalamic–pituitary area on MRI is more important than the level of maximum stimulated GH to predict the growth response to hGH treatment in prepubertal nonacquired GH‐deficient children. Although the persistence of GH deficiency remains to be confirmed during follow‐up by reassessment of GH secretion in isolated GH‐deficient patients with normal MRI findings, further studies are needed to evaluate whether an increased hGH dose in these patients could improve long‐term growth response.
- 17 April 2003
- Published by Wiley in Clinical Endocrinology
- Vol. 58 (5) , 647-652
Presence of magnetic resonance imaging abnormalities of the hypothalamic–pituitary axis is a significant determinant of the first 3 years growth response to human growth hormone treatment in prepubertal children with nonacquired growth hormone deficiency
Summary: objective The factors influencing the highly variable growth response to GH treatment in GH‐deficient children are not fully understood. Despite a real benefit with GH treatment in term of growth response, most of these patients attain a mean adult height below their target height and the strategy to optimise final height has to be improved. The aim of this study was to investigate whether the presence of congenital abnormalities of the hypothalamic–pituitary axis on magnetic resonance imaging (MRI) could be a determinant of the growth response in nonacquired prepubertal GH‐deficient children, and to identify which pretreatment variables most significantly affect the first 3 years growth response to human GH (hGH) therapy.patients and methods The growth response to hGH treatment (0·55 ± 0·1 IU/kg/week) was evaluated in 69 prepubertal children with nonacquired GH deficiency, according to the absence (group A: chronological age = 4·8 ± 2·4 years, n= 37) or the presence (group B: chronological age = 3·4 ± 2·7 years, n= 32) of developmental abnormalities on cerebral magnetic imaging and, after controlling for GH dose, age, height, height velocity (SDS) and body mass index at start of treatment, maximum stimulated GH peak concentration, GH deficiency type (isolated vs. multiple deficiency), parental height, size at birth and sex.results After 3 years of treatment, the mean height gain was significantly higher in patients of group B vs. group A (2·2 ± 1·3 vs. 1·6 ± 1 SDS; P < 0·05). In a multiple regression analysis, age (r2 = 0·19, negatively correlated), pretreatment height velocity (r2 = 0·11, negatively correlated), GH dose (r2 = 0·05, positively correlated) and presence of magnetic resonance imaging developmental abnormalities (r2 = 0·05, positively correlated) were found to significantly explain 40% of the variability in growth response.conclusions The detection of congenital abnormalities in the hypothalamic–pituitary area on MRI is more important than the level of maximum stimulated GH to predict the growth response to hGH treatment in prepubertal nonacquired GH‐deficient children. Although the persistence of GH deficiency remains to be confirmed during follow‐up by reassessment of GH secretion in isolated GH‐deficient patients with normal MRI findings, further studies are needed to evaluate whether an increased hGH dose in these patients could improve long‐term growth response.
- 1 December 2002
- Published by Elsevier in Archives de Pédiatrie
- Vol. 9 (12) , 1283-1287
Prise en charge des enfants avec puberté précoce centrale
- 1 December 2002
- Published by Elsevier in Archives de Pédiatrie
- Vol. 9 (12) , 1283-1287
Prise en charge des enfants avec puberté précoce centrale
- 1 February 2002
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 87 (2) , 575-580
Thyroid Developmental Anomalies in First Degree Relatives of Children with Congenital Hypothyroidism
Congenital hypothyroidism (CH) is most frequently caused by thyroid developmental abnormalities and it has recently been seen to have a familial component. The aim of this study was to investigate whether thyroid developmental abnormalities exist in first degree relatives of CH children with thyroid dysgenesis, an anomaly which, when present, is sometimes asymptomatic. Thyroid ultrasonography and function were evaluated among first degree relatives (n = 241) of 84 isolated CH children with thyroid dysgenesis. The results were compared with those of an unselected control population (n = 217). In 19 individuals (7.9% of cases) belonging to 18 families (21.4%), 21 cases of thyroid developmental abnormalities were detected, whereas only 2 subjects (0.9%) were affected in controls (P < 0.001). These 21 thyroid developmental abnormalities included thyroglossal duct cysts (n = 14), additional thyroid tissue with presence of a pyramidal lobe (n = 3), thyroid hemiagenesis (n = 3), and ectopic thyroid tissue (n = 1). All of these subjects showed normal thyroid function and belonged to nuclear families of CH children with athyreosis (n = 8), ectopic thyroid tissue (n = 9), or hemiagenesis (n = 1). A segregation analysis led to the conclusion that thyroid developmental abnormalities are compatible with an autosomal dominant mode of inheritance with a low penetrance estimated at 21% for asymptomatic thyroid developmental abnormalities and a probability of less than 7% of developing CH for a carrier of the susceptibility allele. In conclusion, these observations support the hypothesis of a common genetic component of the disorder with heterogeneous phenotypes.
- 1 February 2002
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 87 (2) , 575-580
Thyroid Developmental Anomalies in First Degree Relatives of Children with Congenital Hypothyroidism
Congenital hypothyroidism (CH) is most frequently caused by thyroid developmental abnormalities and it has recently been seen to have a familial component. The aim of this study was to investigate whether thyroid developmental abnormalities exist in first degree relatives of CH children with thyroid dysgenesis, an anomaly which, when present, is sometimes asymptomatic. Thyroid ultrasonography and function were evaluated among first degree relatives (n = 241) of 84 isolated CH children with thyroid dysgenesis. The results were compared with those of an unselected control population (n = 217). In 19 individuals (7.9% of cases) belonging to 18 families (21.4%), 21 cases of thyroid developmental abnormalities were detected, whereas only 2 subjects (0.9%) were affected in controls (P < 0.001). These 21 thyroid developmental abnormalities included thyroglossal duct cysts (n = 14), additional thyroid tissue with presence of a pyramidal lobe (n = 3), thyroid hemiagenesis (n = 3), and ectopic thyroid tissue (n = 1). All of these subjects showed normal thyroid function and belonged to nuclear families of CH children with athyreosis (n = 8), ectopic thyroid tissue (n = 9), or hemiagenesis (n = 1). A segregation analysis led to the conclusion that thyroid developmental abnormalities are compatible with an autosomal dominant mode of inheritance with a low penetrance estimated at 21% for asymptomatic thyroid developmental abnormalities and a probability of less than 7% of developing CH for a carrier of the susceptibility allele. In conclusion, these observations support the hypothesis of a common genetic component of the disorder with heterogeneous phenotypes.
- 1 November 2001
- Published by Wiley in Acta Paediatrica
- Vol. 90 (11) , 1249-1256
Influence of severity of congenital hypothyroidism and adequacy of treatment on school achievement in young adolescents: a population-based cohort study
Aim: To evaluate whether precociously treated subjects with congenital hypothyroidism (CH) are at risk of poor school performance in early adolescence, and to investigate which factors affect their school achievement. Methods: All children treated early for congenital hypothyroidism and born in France during the first 7y (1979–1985) of the national screening program for congenital hypothyroidism were selected for the study. School performance during childhood, assessed according to age at entry into the first grade of secondary school, was evaluated as normal (usually 11 y of age) vs late entry (≥12 y). The national register of children with congenital hypothyroidism enabled a comparison to be made with data from the national population for the same school years. Results: School achievement was similar among the 682 patients with CH and in the national population. After an adjustment for the sex and socioprofessional category of the parents, the severity of CH as assessed by the type (athyreosis, the most severe vs other types), the initial low serum T4 levels (≤53 nmol/L vs >53 nmol/L), and the profound bone maturation delay (absence vs presence of the two knee epiphyseal ossification centres at diagnosis), initially low L-thyroxine dosage (below vs ≥7 μg/kg/day), the absence of near normalization of thyroid hormone levels after 15 d of treatment and poor adequacy of treatment throughout childhood were associated with an increased risk of school delay. School achievement was unaffected by the age at start of treatment (mean age = 22.8 ± 6.8 d). In a multivariate logistic regression analysis, recurrent episodes of insufficiently suppressed TSH levels (≥15mUi/L at least four times during follow-up from the age of 6 mo onwards) were the most important variable associated with school delay. Conclusion: Careful follow-up of the adequacy of treatment is required throughout childhood, to reduce the risk of school delay.
- 1 November 2001
- Published by Wiley in Acta Paediatrica
- Vol. 90 (11) , 1249-1256
Influence of severity of congenital hypothyroidism and adequacy of treatment on school achievement in young adolescents: a population-based cohort study
Aim: To evaluate whether precociously treated subjects with congenital hypothyroidism (CH) are at risk of poor school performance in early adolescence, and to investigate which factors affect their school achievement. Methods: All children treated early for congenital hypothyroidism and born in France during the first 7y (1979–1985) of the national screening program for congenital hypothyroidism were selected for the study. School performance during childhood, assessed according to age at entry into the first grade of secondary school, was evaluated as normal (usually 11 y of age) vs late entry (≥12 y). The national register of children with congenital hypothyroidism enabled a comparison to be made with data from the national population for the same school years. Results: School achievement was similar among the 682 patients with CH and in the national population. After an adjustment for the sex and socioprofessional category of the parents, the severity of CH as assessed by the type (athyreosis, the most severe vs other types), the initial low serum T4 levels (≤53 nmol/L vs >53 nmol/L), and the profound bone maturation delay (absence vs presence of the two knee epiphyseal ossification centres at diagnosis), initially low L-thyroxine dosage (below vs ≥7 μg/kg/day), the absence of near normalization of thyroid hormone levels after 15 d of treatment and poor adequacy of treatment throughout childhood were associated with an increased risk of school delay. School achievement was unaffected by the age at start of treatment (mean age = 22.8 ± 6.8 d). In a multivariate logistic regression analysis, recurrent episodes of insufficiently suppressed TSH levels (≥15mUi/L at least four times during follow-up from the age of 6 mo onwards) were the most important variable associated with school delay. Conclusion: Careful follow-up of the adequacy of treatment is required throughout childhood, to reduce the risk of school delay.
- 1 January 2000
- p. 1257-9
Syndrome X: a consequence of intra-uterine malnutrition?
The long-term consequences of intra-uterine growth retardation (IUGR) on postnatal growth and development are well known. More recently, several epidemiological and clinical studies in adults have provided evidence that low birth weight is an independent risk factor for the syndrome of insulin resistance in mid to late adulthood. In the present study, we demonstrated that individuals born small for gestational age showed isolated insulin resistance in early adulthood with no impairment of serum lipid concentrations and blood pressure at this age. Angiotensin-I converting enzyme gene polymorphism has also been shown to modulate the effect on insulin resistance of being small for gestational age. Fetal malnutrition may be the critical factor to explain the relationship between IUGR and insulin resistance which might be modulated by genetic factors.
- 1 January 2000
- p. 1257-9
Syndrome X: a consequence of intra-uterine malnutrition?
The long-term consequences of intra-uterine growth retardation (IUGR) on postnatal growth and development are well known. More recently, several epidemiological and clinical studies in adults have provided evidence that low birth weight is an independent risk factor for the syndrome of insulin resistance in mid to late adulthood. In the present study, we demonstrated that individuals born small for gestational age showed isolated insulin resistance in early adulthood with no impairment of serum lipid concentrations and blood pressure at this age. Angiotensin-I converting enzyme gene polymorphism has also been shown to modulate the effect on insulin resistance of being small for gestational age. Fetal malnutrition may be the critical factor to explain the relationship between IUGR and insulin resistance which might be modulated by genetic factors.